title: Effect of olmesartan on leukocyte recruitment in choroid-sclera complex in hypercholesterolemia model.
abstract: OBJECTIVE
  Demonstrate that the blockade of angiotensin II AT-1 receptors, through the systemic administration of olmesartan, can reduce the MCP-1 expression and the resulting macrophage accumulation in the choroid and sclera of hypercholesterolemic rabbits.
  
  
  METHODS
  Thirty-two New Zealand rabbits were divided into 3 groups: group I (GI) was fed a standard rabbit diet; group II (GII) was fed a hypercholesterolemic diet; and group III (GIII) was fed a hypercholesterolemic diet plus olmesartan. Serum levels of total cholesterol, triglyceride, HDL cholesterol, and blood glucose were determined in fasting rabbits at the beginning of the experiment and on the day of euthanasia. The choroid and sclera were submitted to morphometric analysis as well as immunohistochemical analysis with MCP-1 and RAM-11 (macrophage marker) antibodies.
  
  
  RESULTS
  No abnormality was detected in GI. Group II and III had significant increases in choroid-sclera complex thicknesses when compared with group I (P<0.001). GII showed a significant increase in immunoreactivity for MCP-1 in relation to GI (P=0.001) and GIII (P=0.004). GII showed a significant increase in immunoreactivity for RAM-11 of the choroid-sclera complex in relation to GI (P<0.001) and GIII (P=0.034). A significant increase in immunoreactivity for RAM-11 was observed in GIII in relation to GI (P=0.008).
  
  
  CONCLUSIONS
  Olmesartan reduced the MCP-1 expression and the resultant macrophage accumulation in the choroid-sclera complex of hypercholesterolemic rabbits.
authors.affiliation: 1 Pontificia Universidade Catolica do Parana , Curitiba, Brazil .
authors.forename: Rogil Jose de Almeida
authors.initials: RJ
authors.lastname: Torres
authors.forename: Lucia
authors.initials: L
authors.lastname: de Noronha
authors.forename: Antonio Marcelo Barbante
authors.initials: AM
authors.lastname: Casella
authors.forename: Sarah Fagundes
authors.initials: SF
authors.lastname: Grobe
authors.forename: Isabela de Carvalho
authors.initials: Ide C
authors.lastname: Martins
authors.forename: Regiane do Rocio de Almeida
authors.initials: Rdo R
authors.lastname: Torres
authors.forename: Andrea
authors.initials: A
authors.lastname: Luchini
authors.forename: Mario Claudio Soares
authors.initials: MC
authors.lastname: Sturzeneker
authors.forename: Caroline Luzia de Almeida
authors.initials: CL
authors.lastname: Torres
authors.forename: Dalton Bertolim
authors.initials: DB
authors.lastname: Precoma
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D018932:Chemokine CCL2 / Q000276:immunology; D002634:Chemotaxis, Leukocyte / Q000187:drug effects* / Q000276:immunology; D002829:Choroid / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008264:Macrophages / Q000276:immunology; D008268:Macular Degeneration / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D008297:Male; D011817:Rabbits; D012590:Sclera / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D013777:Tetrazoles / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D015415:Biomarkers; D001786:Blood Glucose; D018932:Chemokine CCL2; D007093:Imidazoles; D008055:Lipids; D013777:Tetrazoles; C437965:olmesartan